Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company was transferred to the archive: financial data is no longer updated!

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Vertex Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Accounts payable 1.06 1.32 0.95 0.99 1.13 1.05 1.23 1.10 1.26 1.78 1.99 1.92 1.87 2.09 2.41 2.31 2.14 2.12 1.95 2.01 3.02
Accrued expenses 12.65 11.96 15.07 15.13 14.15 13.43 15.62 15.20 13.99 15.35 17.93 17.75 17.19 19.07 17.79 15.00 12.99 13.42 11.19 10.80 10.96
Senior secured term loan, current portion 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.41 8.69 5.88
Credit facility 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.36 0.00 0.00 0.00
Other current liabilities 2.35 2.70 1.70 1.49 2.02 1.57 1.63 1.61 1.66 0.81 1.56 1.72 1.86 1.60 2.03 1.73 1.49 1.46 3.15 2.93 2.33
Current liabilities 16.05% 15.98% 17.73% 17.61% 17.30% 16.05% 18.48% 17.90% 16.91% 17.94% 21.48% 21.39% 20.93% 22.77% 22.22% 19.03% 16.62% 27.36% 27.70% 24.44% 22.19%
Long-term finance lease liabilities 4.38 4.59 4.84 5.11 5.99 6.47 7.21 7.84 8.56 9.31 12.48 13.32 14.63 16.47 17.74 16.75 17.96 18.00 19.34 19.88 20.55
Long-term operating lease liabilities 3.04 2.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred tax liabilities 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.22 0.24 0.18 0.33 4.16 4.60 4.63 5.11 5.21 4.51
Long-term contingent consideration 1.53 1.61 1.67 1.83 2.00 2.12 2.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Senior secured term loan, excluding current portion 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.94 6.01
Other long-term liabilities 0.88 0.92 3.79 1.85 2.04 2.20 2.07 2.17 2.34 1.74 2.34 2.45 2.71 3.00 3.33 3.22 3.72 3.82 1.55 1.68 1.87
Long-term liabilities 9.83% 10.10% 10.30% 8.79% 10.04% 10.80% 11.61% 10.01% 10.90% 11.05% 15.02% 15.99% 17.58% 19.64% 21.40% 24.13% 26.27% 26.45% 26.00% 29.71% 32.95%
Total liabilities 25.88% 26.08% 28.03% 26.40% 27.34% 26.85% 30.09% 27.92% 27.81% 28.99% 36.49% 37.38% 38.51% 42.41% 43.62% 43.17% 42.89% 53.80% 53.70% 54.14% 55.14%
Preferred stock, $0.01 par value; none issued and outstanding 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Common stock, $0.01 par value 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.06 0.06 0.06 0.07 0.08 0.08 0.08 0.08 0.09 0.10 0.10
Additional paid-in capital 61.90 67.17 70.06 77.75 86.54 95.42 102.04 107.55 114.26 118.82 161.08 169.70 185.03 201.84 219.93 207.21 224.56 224.62 246.38 249.13 251.74
Accumulated other comprehensive income (loss) -0.27 -0.58 -0.36 -0.14 0.15 -0.02 0.25 -0.05 0.09 0.01 0.01 -0.11 -1.01 -0.33 -0.79 -0.66 0.54 0.73 -0.15 -0.13 -0.20
Retained earnings (accumulated deficit) 12.48 7.31 2.25 -4.04 -14.06 -22.28 -32.42 -35.46 -42.20 -47.86 -98.25 -107.69 -123.35 -144.38 -163.22 -155.75 -174.28 -185.51 -207.18 -210.59 -213.17
Total Vertex shareholders’ equity 74.12% 73.92% 71.97% 73.60% 72.66% 73.15% 69.91% 72.08% 72.19% 71.01% 62.89% 61.96% 60.74% 57.21% 56.00% 50.87% 50.90% 39.93% 39.15% 38.50% 38.47%
Noncontrolling interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61 0.66 0.75 0.39 0.38 5.96 6.20 6.27 7.16 7.36 6.40
Total shareholders’ equity 74.12% 73.92% 71.97% 73.60% 72.66% 73.15% 69.91% 72.08% 72.19% 71.01% 63.51% 62.62% 61.49% 57.59% 56.38% 56.83% 57.11% 46.20% 46.30% 45.86% 44.86%
Total liabilities and shareholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-Q (filing date: 2021-04-30), 10-K (filing date: 2021-02-11), 10-Q (filing date: 2020-10-30), 10-Q (filing date: 2020-07-31), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-13), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-08-01), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-13), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-15), 10-Q (filing date: 2017-10-30), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-04-28), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-10-31), 10-Q (filing date: 2016-08-01), 10-Q (filing date: 2016-05-03).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Vertex Pharmaceuticals Inc.’s current liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc.’s long-term liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Vertex Pharmaceuticals Inc.’s total liabilities as a percentage of total liabilities and shareholders’ equity decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Total Vertex shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Vertex Pharmaceuticals Inc.’s total Vertex shareholders’ equity as a percentage of total liabilities and shareholders’ equity increased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.